Search Results

You are looking at 21 - 30 of 207 items for :

  • Refine by Access: All x
Clear All
Full access

-cell transplant experience. Close monitoring in the hospital...” ➤ 2nd bullet was revised: “Hospitalization is warranted for patients with at the first sign of CRS or neurotoxicity (including fever, hypotension, or change in mental status) is warranted

Full access

Caitlin Zebley, Charmaine C Brown, Tian Mi, Yiping Fan, Shanta Alli, Shannon Boi, Giovanni Galletti, Enrico Lugli, Deanna Langfitt, Jean-Yves Metais, Timothy Lockey, Michael Meagher, Brandon Triplett, Aimee Talleur, Stephen Gottschalk, and Ben Youngblood

by cross-referencing our epigenetic data with publicly available transcriptional profiles for antigen-specific effector and long-lived memory CD8 T cells from individuals vaccinated for yellow fever. Furthermore, we show that CAR T cells were unable

Full access

Demetrios N. Kyriacou, Borko Jovanovic, and Olga Frankfurt

suppression with resultant leukopenia that renders these patients susceptible to serious infections, often with fever as the only clinical finding. 5 – 8 This complication, known as febrile neutropeni a (FN), occurs in 10% to 30% of patients undergoing

Full access

David P. Steensma

low-grade fever during the night, and the PICC team’s policy is that all cultures must be negative for 48 hours before a line can be placed. (This scenario is not difficult for me to visualize, since it happened to me twice recently.) You might wait 48

Full access

Beryl McCormick

: Perez CA, Brady LW, eds. Principles and Practices of Radiation Oncology . Philadelphia : J B Lippincott ; 1987 : 317 – 352 . 2. Warren S . Preliminary study of the effect of artificial fever upon hopeless tumor cases . Am J Roentgenol

Full access

Ernesto Munoz and Allison Carilli

. Our patient has a rearrangement of the MYC and BCL-6 oncogenes which is the least common and is considered to have a worse prognosis. HGBL commonly presents with extranodal disease, lymphadenopathy, fever, night sweats, weight loss, loss of appetite

Full access

Pranab Kumar Sahoo, Sinjini Sarkar, Sutapa Mahata, Ranita Pal, Tanuma Mistry, Sushmita Ghosh, Trisha Choudhury, Sriparna Datta, Anup Kumar Bhowmick, Kalyan Kusum Mukherjee, and Vilas D Nasare

toxicities like anaemia (13.3%) followed by neutropenia (2.4%) and thrombocytopenia (2.4%) whereas non-hematological toxicities include diarrhoea (30.5%), vomiting (26.6%), fever (23.1%), myalgia (19.7%) and mucositis (5.41%). 82 (40.39%) patients succumbed

Full access

Elizabeth Marrett, Winghan Jacqueline Kwong, Jinlin Song, Ameur M. Manceur, Selvam Sendhil, and Eric Wu

/pneumonitis (3.0), infection/sepsis (2.1), nausea and vomiting (1.9), fever (1.7), and diarrhea (1.5). Conclusions : After osimertinib discontinuation, plat-chemo regimens were the most common subsequent LOT, followed by reuse of EGFR-TKIs. Overall, the

Full access

Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma, and Dorothy A. Shead

); management of neutropenic fever; management of site-specific infections (eg, pneumonia, abdominal infections, catheter-associated infections); and, importantly, prevention of infectious complications, including the use of antimicrobial prophylaxis and

Full access

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel, and Chun Chao

administration in the absence of fever/infection; (3) received dose-dense chemotherapy regimens or weekly regimens; (4) had bone marrow/stem cell transplantation; or (5) were patients of Orange County Medical Center if their cancer was diagnosed before 2007, for